What is adiposopathy (sick fat) and what are the recommended management strategies?

Adiposopathy: Definition and Management

Adiposopathy, or "sick fat," is a pathological state where adipose tissue becomes dysfunctional due to adipocyte hypertrophy and visceral fat accumulation, leading to pathogenic metabolic and immune responses that directly cause metabolic diseases including type 2 diabetes, hypertension, and dyslipidemia. 1

What is Adiposopathy?

Adiposopathy represents the underlying pathophysiological mechanism linking excess adiposity to metabolic disease. The term describes anatomical and functional abnormalities in adipose tissue that occur when positive caloric balance overwhelms the tissue's capacity to safely store energy 2.

Key pathophysiological features include:

• Adipocyte hypertrophy - enlarged, dysfunctional fat cells that cannot properly store lipids
• Visceral adiposity - pathogenic fat accumulation in the abdominal cavity
• Impaired adipogenesis - inability to recruit new, healthy adipocytes
• Chronic inflammation - pathogenic immune responses from dysfunctional adipose tissue
• Excessive free fatty acid release - lipotoxicity affecting other organs 3, 4

This differs fundamentally from simple obesity: not all patients with elevated BMI have adiposopathy, and conversely, some metabolically unhealthy patients may have normal BMI but dysfunctional adipose tissue 5. The dysfunction causes ectopic fat deposition in liver, muscle, and pancreas, driving insulin resistance and metabolic disease 4, 6.

Management Strategies

The 2025 AACE guidelines establish that adiposopathy requires treatment as Adiposity-Based Chronic Disease (ABCD), with intensity matched to disease severity rather than BMI alone 1.

Staging and Treatment Intensity

Stage 1 ABCD (excess adiposity without complications):

• Intensive lifestyle intervention to prevent adiposopathy progression
• Consider pharmacotherapy for primary prevention

Stage 2 ABCD (mild-to-moderate obesity-related complications):

• Combination therapy: lifestyle + pharmacotherapy
• Target ≥15% weight loss to reverse adipose tissue dysfunction 4

Stage 3 ABCD (severe complications):

• Aggressive multimodal therapy including bariatric surgery consideration
• Pharmacotherapy with highest efficacy agents 1

Specific Therapeutic Approaches

Pharmacotherapy targets adiposopathy through multiple mechanisms:

• GLP-1 receptor agonists - reduce adipocyte size, decrease visceral fat, improve adipose tissue endocrine function 1, 4
• SGLT2 inhibitors - reduce ectopic fat accumulation, improve metabolic parameters 4
• Metformin - improves adipose tissue insulin sensitivity, reduces inflammation 4, 6
• Combination phentermine/topiramate - affects both central appetite regulation and peripheral fat metabolism 7

The evidence strongly supports that weight loss of ≥15% body weight is required to meaningfully reverse adiposopathy and improve metabolic disease 4. Lesser degrees of weight loss may improve symptoms but do not adequately address the underlying adipose tissue dysfunction.

Bariatric surgery effectively treats adiposopathy through:

• Acute reduction in adipocyte size
• Preferential loss of visceral adiposity
• Favorable alterations in adipose tissue endocrine responses
• Improved adipogenesis capacity 8

Lifestyle Interventions

Dietary approach:

• Hypocaloric diet to induce negative energy balance
• Focus on reducing visceral adiposity specifically
• Evidence-based dietary patterns customized to patient adherence 9

Exercise prescription:

• Gradual increase to 200-300 minutes weekly of moderate-to-vigorous intensity
• Critical for weight maintenance and preventing metabolic adaptation
• Reduces adipose tissue inflammation 9

Critical Management Principles

The 2025 AACE guidelines emphasize complication-centric care rather than BMI-focused treatment 1. This means:

• Assess for obesity-related complications and diseases (ORCD) at every visit
• Stage disease severity based on complications, not weight alone
• Match treatment intensity to complication severity
• Target improvement in metabolic parameters as primary outcomes

Address weight-promoting medications:

• Minimize or eliminate insulin, sulfonylureas, certain antipsychotics/antidepressants, and corticosteroids when possible 1

Long-term management is mandatory - adiposopathy is a chronic disease requiring lifelong treatment to prevent weight regain and recurrence of metabolic complications 1. The body biologically defends its fat mass through neuroendocrine mechanisms, explaining why behavioral interventions alone typically fail long-term 1.

Common Pitfalls to Avoid

• Do not rely on BMI alone - it provides no information about adipose tissue function or metabolic health 1, 5
• Do not undertreate based on arbitrary weight thresholds - treat based on presence and severity of complications 1
• Do not stop treatment after initial weight loss - maintenance therapy is essential to prevent adiposopathy recurrence 1
• Do not ignore psychological factors - address weight bias, stigma, depression, and disordered eating as barriers to treatment success 1

The fundamental therapeutic goal is "healing" rather than "exterminating" adipocytes - interventions should restore healthy adipose tissue function, not simply reduce fat mass 6. This requires homeostatic approaches targeting the neuroimmunoendocrine dysregulation underlying adiposopathy.